Cited by 550Gastrointestinal motility and disordersStatistical Methods in Clinical TrialsEthics in Clinical Research

The DOI matches its Crossref record; 147 of the 151 references it cites were found in a registry or an index.

Design of Treatment Trials for Functional Gastrointestinal Disorders

Irvine, E. Jan, Tack, Jan, Crowell, Michael D., Gwee, Kok Ann, Ke, Meiyun, Schmulson, Max J., Whitehead, William E., Spiegel, Brennan·2016·Gastroenterology

DOI 10.1053/j.gastro.2016.02.010

Open this paper in CoChat — free account

Abstract

This article summarizes recent progress and regulatory guidance on design of trials to assess the efficacy of new therapies for functional gastrointestinal disorders (FGIDs). The double-masked, placebo-controlled, parallel-group design remains the accepted standard for evaluating treatment efficacy. A control group is essential, and a detailed description of the randomization process and concealed allocation method must be included in the study report. The control will most often be placebo, but for therapeutic procedures and for behavioral treatment trials, respectively, a sham procedure and control intervention with similar expectation of benefit, but lacking the treatment principle, are recommended. Investigators should be aware of, and attempt to minimize, expectancy effects (placebo, nocebo, precebo). The primary analysis should be based on the proportion of patients in each treatment arm who satisfy a treatment responder definition or a prespecified clinically meaningful change in a patient-reported outcome measure. Data analysis should use the intention-to-treat principle. Reporting of results should follow the Consolidated Standards for Reporting Trials guidelines and include secondary outcome measures to support or explain the primary outcome and an analysis of harms data. Trials should be registered in a public location before initiation and results should be published regardless of outcome.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2016.02.010

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Untitled work
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
The McGill Pain Questionnaire: Major properties and scoring methods
Melzack, R. (1975) · Pain · doi:10.1016/0304-3959(75)90044-5 · Cited by 6,873
Multilevel analysis : an introduction to basic and advanced multilevel modeling
Snijders, T. A. B., & Bosker, R. (1999) · Cited by 6,830
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Measurement of health status
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Sickness Impact Profile: Development and Final Revision of a Health Status Measure
Bergner, M., Bobbitt, R. A., Carter, W. B., & Gilson, B. S. (1981) · Medical Care · doi:10.1097/00005650-198108000-00001 · Cited by 4,619
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
The MOS Short-form General Health Survey: Reliability and Validity in a Patient Population
Stewart, A. L., Hays, R. D., & Ware, J. E. (1988) · Medical Care · doi:10.1097/00005650-198807000-00007 · Cited by 3,339

Flagged first, then by citations

Show all 151 references

4 of the 151 references couldn’t be matched to a known paper.

Sorted by citations

Items 501–550 of 550

Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders
Agrawal, A., & Whorwell, P. J. (2006) · Therapy · doi:10.1586/14750708.3.4.475
The role of treatment with proton pump inhibitors and anti-Helicobacter therapy in functional dyspepsia
van Zanten, S. V. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02795-2
Effects of Cetirizine on Symptoms and Gastric Mucosal Mast Cells in Patients with Functional Dyspepsia
Shirazinezhad, K. M., Eftekharossadat, A., & Sadrkabir, M. (2014) · GOVARESH
Are withdrawal trials in paediatric rheumatic disease helpful
Kremer, J. M., & Ruperto, N. (2008)
Development of an integrated psychological and biological assessment protocol: the role of the brain-gut axis in irritable bowel syndrome
Nelson, E. (2012) · Swinburne figshare (Swinburne University of Technology) · doi:10.25916/sut.26271883
Helicobacter pyloriEradication in Non-Ulcer Dyspepsia: Clearing up the Controversy
Fallone, C. A. (2004) · Canadian Journal of Gastroenterology · doi:10.1155/2004/171275
Effectiveness of probiotic Bifidobacterium animalis DN-173010 in the management of constipation-predominant irritable bowel syndrome in black South African women
Rammbwa, M. Y. (2013)
Effekt av Lactobacillus plantarum 299v på symtomlindring hos patienter med IBS - En systematisk översiktsartikel
Ingesson, M., & Wellander, A. (2016) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Manfaat Pemberian Probiotik pada Diare Akut
Rahmi, D., & Gayatri, P. (2016) · Sari Pediatri · doi:10.14238/sp17.1.2015.76-80
Effectiveness of probiotic Bifidobacterium animalis DN-173010 in the management of constipation-predominant irritable bowel syndrome in black South African women
Blaauw, R. (2014)
Treatment of Functional Bowel Disorders With Prebiotics and Probiotics
Hod, K., & Ringel, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00038-0
Clinical, psychosocial and therapeutic aspects of irritable bowel syndrome : results of cohort studies and aprobiotic intervention trial
Thijssen, A. Y. (2015) · Research Publications (Maastricht University) · doi:10.26481/dis.20151119at
BRIEF COMMUNICATION A Very Low-Carbohydrate Diet Improves Symptoms and Quality of Life in Diarrhea-Predominant Irritable Bowel Syndrome
Austin, G. L., Dalton, C. B., Hu, Y., Morris, C. B., Hankins, J. S., Weinland, S. R., Westman, E. C., Yancy, W. S., & Drossman, D. A. (2009)
Placebo effect in functional gastrointestinal disorders: Part of the gut-brain axis?
Matsubara, Ó. T., Cossío, S. S., & Kimura, S. Y. T. (2018) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2018.09.00332
Dolor abdominal recidivante en pediatría
Weydert, J. A. (2009) · Elsevier eBooks · doi:10.1016/b978-84-458-1911-1.50045-2
El efecto placebo, nocebo y precebo en los trastornos funcionales digestivos: ¿imaginación o realidad?
Sobrino-Cossio, S. R., & Teramoto-Matsubara, O. (2019) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.18000014
Diagnostic modalities and outcome measures in upper gastrointestinal disorders
Smeets (2019) · doi:10.26481/dis.20190927fs
Traditional treatments for irritable bowel syndrome: the state of our knowledge
Törnblom, H. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30418-2
Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future objectives
Maixent, J. M., Pons, O., Sennoune, S. R., & Sadrin, S. (2020) · Archives of Clinical Gastroenterology · doi:10.17352/2455-2283.000075
Fibra en los trastornos de la interacción intestinocerebro
García-Zermeño, K. R., & Troche, J. M. R. (2021) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.21000010
Acupuncture For The Treatment of Diarrhoea-Predominant Irritable Bowel Syndrome (ATIBS-D): A Pilot Randomized Controlled TrialPreprint
Qi, L., Yang, J.-W., Yan, S.-Y., Tu, J.-F., She, Y., Li, Y., Chi, L.-L., Wu, B.-Q., & Liu, C.-Z. (2021) · Research Square · doi:10.21203/rs.3.rs-1050148/v1
Effects of a thermal reservoir on variational functions in open systems (18 pages)
Stenholm, S., & Jakob, M. (2004) · Physical Review A
Functional Dyspepsia
van Zanten, S. J. V. (2004) · doi:10.1002/9780470987025.ch8
Discussion II
(2002) · Gut · doi:10.1136/gut.50.suppl_4.iv31
Editorial
Saps, M., & Schmulson, M. J. (2019) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.m19000010
Self-citation
Faculty Opinions recommendation of Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial.
Brüssow, H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733102322.793562126
Reply
Creed, F. H. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.09.009
Outcome of a public consultation on the draft guidance of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific requirements for health claims related to the immune system, the gastrointestinal tract and defence against pathogenic microorganisms
(EFSA), E. F. S. A. (2016) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2016.en-985
Response to comments on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific substantiation of a health claim related to Bimuno® GOS and reducing gastro‐intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006
(EFSA), E. F. S. A. (2015) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2015.en-728
Applying Novel Nutrient Drink to Clinical Trial of Functional Dyspepsia
Lim, C., Choi, M., Baeg, M. K., Moon, S. J., Kim, J. S., Cho, Y. K., Park, J. M., Lee, I. S., Kim, S. W., & Choi, K. Y. (2014) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.20.2.219
Faculty Opinions recommendation of Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome.
Chey, W. Y. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725585464.793547363
Understanding the patient perspective for treatment outcomes and preferences in functional bowel disorders
Sturkenboom, R. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20221109rs
From healthy defecation to functional constipation in children and adults : a clinical and microbiological perspective
Wegh, C. A. M. (2022) · doi:10.18174/576006
Prescribing patterns and analyzing the usage of corticosteroid therapy at tertiary care hospital
Pavithra, C. H., Mahesh, C., Prasanth Kumar, D., Sandhya, M., Himasree, N., Sai Kumar, T., Vani, K., & Swathi Krishna, K. (2024) · UPI Journal of Pharmaceutical Medical and Health Sciences · doi:10.37022/jpmhs.v7i1.99
Asociación Española de Neurogastroenterologia y Motilidad (ASENEM) updated review on the management of functional abdominal pain
Serra, J., Aguilar, A., Barba, E., Ríos, C. C. D. L., Pravia, L. G., Martı́nez, V., & Falcón, B. S. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2024.04.072
Planning a Clinical Development Programme for Medicinal Products for Functional Gastrointestinal Disorders
Avakiants, I. P., Gerasimets, E. A., Петрова, Е. С., & Goryachev, D. V. (2024) · Ведомости Научного центра экспертизы средств медицинского применения · doi:10.30895/1991-2919-2025-15-1-82-91
Blinding: Who and how?
Ramsey, M. L., Papachristou, G. I., & Han, S. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-821426-8.00055-8
Additional file 2 of Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial
Zheng, Y., Ching, J., Cheng, C. W., Lam, W. C., Chan, K. L., Zhang, X., Lam, P. Y., Wu, X. Y., Zhong, L. L. D., Cao, P. H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17007047
Additional file 1 of Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial
Zheng, Y., Ching, J., Cheng, C. W., Lam, W. C., Chan, K. L., Zhang, X., Lam, P. Y., Wu, X. Y., Zhong, L. L. D., Cao, P. H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17007044
Additional file 4 of Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial
Zheng, Y., Ching, J., Cheng, C. W., Lam, W. C., Chan, K. L., Zhang, X., Lam, P. Y., Wu, X. Y., Zhong, L. L. D., Cao, P. H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17007053
Additional file 1 of Effect of a low-FODMAP diet for the management of functional abdominal pain disorders in children: a study protocol for a randomized controlled trial
Stróżyk, A., Horvath, A., Muir, J. G., & Szajewska, H. (2021) · Figshare · doi:10.6084/m9.figshare.13514704
Additional file 3 of Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial
Zheng, Y., Ching, J., Cheng, C. W., Lam, W. C., Chan, K. L., Zhang, X., Lam, P. Y., Wu, X. Y., Zhong, L. L. D., Cao, P. H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17007050
Combination of Dietary Fibers From Different Food Origins as a Treatment for Adults With Functional Constipation: A Randomized Clinical Trial
Minno, A. D., Morone, M. V., Buccato, D. G., Lellis, L. F. D., Ullah, H., Cerqua, A., Piccinocchi, R., Riccioni, C. V., Larsen, D., Baldi, A., et al. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.72048
“In addition, they were provided with guidelines on proper defe-cation posture (a pictogram was given at T0 (Irvine et al. 2016)), the recommended daily fluid intake of two liters, which was recorded in the Bowel Function Diary and the requirement to document any pharmacological treatments taken,…”
Rifaximin Combined with Probiotics for Functional Diarrhea: A Prospective Cohort StudyPreprint
Zhou, J., Yin, G.-J., Liu, Y., & Feng-jie, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10114100/v1
Comparing the Effect of Written and Biofeedback Device‐Guided Breathing Exercises on the Severity of Irritable Bowel Syndrome Symptoms
Chakraborty, S. (2026) · Lifestyle Medicine · doi:10.1002/lim2.70069
Meta‐Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Silveira, I. B., SÜFFERT, L. C., Leite, G. A. P. D., Tomé, M. R., de Lima, S. Q. L., Leite, G. A. P. D., Moraes, B. D. F., Passos, P. R. C., & Cançado, G. G. L. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70915
“High placebo responses may compromise the ability of a trial to distinguish an effective intervention from an inactive control [10].”
Investigating the contextual modulation of postoperative gastrointestinal motility: a methodological feasibility study combining a standardized intervention protocol with wireless motility capsule monitoring
Coenen, M., Schedlowski, M., Hartmann, G., Kalff, J. C., Büttner, T., & Vilz, T. O. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1913608
“Most placebo research in gastrointestinal disorders relies on patient-reported outcomes susceptible to expectation bias (Irvine et al., 2016; Bosman et al., 2021).”
Registered therapeutic trials in adults with functional dyspepsia: a scoping review of design and registration characteristics
Yao, K., Lang, Y., Deng, W., Zhang, S., Liu, S., & Leng, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1956161
“The interpretation of treatment effects depends in part on how trials define their populations, handle overlapping conditions, select outcomes, apply masking, and specify treatment and follow-up periods (4, 5).”
Clinical Outcomes of Rifaximin Combined with Probiotics in Patients with Functional Diarrhea A Prospective Cohort StudyPreprint
Zhou, J., Yin, G.-J., Liu, Y.-X., & Feng-jie, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10907334/v1
Syndrome de l’intestin irritable: traitements conventionnels et alternatifs
Coffin, B. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0237-4_10 · Cited by 1

Authors: Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B.
Affiliations: St. Michael's Hospital (CA)
Universitair Ziekenhuis Leuven (BE)
Mayo Clinic (US)
National University of Singapore (SG)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Hospital General de México (MX)
University of North Carolina at Chapel Hill (US)
Cedars-Sinai Medical Center (US)
Corresponding author: Tack, Jan
ORCID: Tack, Jan
Crowell, Michael D.
Gwee, Kok Ann
Schmulson, Max J.
Whitehead, William E.
Spiegel, Brennan
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2016-05
Volume: 150
Issue: 6
Pages: 1469-1480.e1
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2016.02.010
OpenAlex: W2065994042
Cited by: 550
References: 151
Citations by year: 2026: 7 · 2025: 7 · 2024: 17 · 2023: 12 · 2022: 19 · 2021: 25 · 2020: 22 · 2019: 22 · 2018: 31 · 2017: 22 · 2016: 20
FWCI: 5.29
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
Keywords: functional gastrointestinal disorders, clinical trial design, sham procedure, expectancy effects, nocebo, patient-reported outcome measures, intention-to-treat analysis, CONSORT guidelines, clinical trial registration, regulatory guidelines
MeSH terms: Gastrointestinal Diseases, Research Design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Design of Treatment Trials for Functional Gastrointestinal Disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks